News & Events
On August 8, 2024, Guangzhou Lupeng Pharmaceutical Co., Ltd. (Lupeng Pharma), an innovative pharmaceutical company focusing on malignant tumors and autoimmune diseases，and Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK), China's leading innovation-driven pharmaceutical company, jointly announced that the two parties have entered into a licensing agreement on a small molecule Bruton's tyrosine kinase inhibitor (BTKi) LP-168 (“LP-168”) independently developed by Lupeng Pharma .
Pursuant to the licensing agreement, Hansoh Pharma has obtained an exclusive license from Lupeng Pharma to develop and commercialize LP-168 in all non-tumor indications within China (including Hong Kong, Macau and Taiwan). Hansoh Pharma will be responsible for the research and development (“R&D”) , regulatory approval, manufacturing and commercialization of LP-168 in all non-tumor indications in China, and will pay an upfront payment and potential payments upon reaching R&D, regulatory and sales-based commercial milestones of up to RMB729 million in total, plus tiered royalties up to double-digit on future product sales.
LP-168 is a small molecule Bruton's tyrosine kinase inhibitor (BTKi). As of the date of this announcement, Lupeng Pharma is conducting various clinical studies on LP-168, with the highest stage of development in China being a Phase II pivotal clinical trial of tumor.
Dr. Fenlai Tan, the Chairman, CEO and CMO of Lupeng Pharmaceuticals, said: "LP-168, as the next generation BTKi, has demonstrated outstanding safety profile and unique mechanism advantages in previous clinical studies. We believe that the comprehensive experience and resource from Hansoh Pharmaceuticals will accelerate the clinical development and commercialization of LP-168 in autoimmune diseases. Moreover, this will bring important breakthrough to the landscape of available treatments of immune disorders in China and even globally."
"Hansoh Pharma is actively seeking high-value and potential blockbuster products in the non-tumor field,” said Ms Eliza Sun, Executive Director of the Board at Hansoh,“Through this collaboration with Lupeng Pharma, we will further expand our pipeline portfolio for the treatment of autoimmune disorders and provide more medication options for patients with chronic autoimmune diseases."
About Lupeng Pharmaceutical
Lupeng Pharmaceutical was co-founded by Dr. Tan Fenlai and Dr. Chen Yi in Guangzhou in June 2018. The company focus on key targets such as BTK, Bcl-2, and Bcl-xL in hematological tumors, and it dedicated to developing innovative drugs for cancer and autoimmune diseases.
With strong R&D capacity, Lupeng is at the cutting-edge of medical innovation and has more than 10 programs, among which the core programs Rocbrutinib (LP-168) and Lacutoclax (LP-108) have been approved by the National Medical Products Administration for pivital registration trials. Rocbrutinib, Lacutoclax, and LP-118 are highly competitive and are expected to become the BIC (Best-in-Class) new drugs.
Lupeng has continuously received investment and support from many international and domestic widely known biopharmaceutical venture capital funds. Lupeng is committed to becoming an innovative and globally competitive biopharmaceutical company with a whole-industry-chain layout that encompasses R&D, manufacturing and commercialization. in the Greater Bay Area.
About Hansoh Pharma
Hansoh Pharma is a leading pharmaceutical company in Greater China driven by innovation. It is committed to the treatment of major diseases in the areas of oncology, anti-infections, CNS diseases, metabolic diseases, as well as autoimmune diseases, and is dedicated to improving human health through continuous innovation. Hansoh Pharma has been ranked among the top 100 global pharmaceutical companies and the top 3 best industrial enterprises in China in terms of pharmaceutical R&D pipeline for several years, and is a national key high-tech enterprise and a national technology innovation demonstration enterprise. Hansoh Pharma was listed on the Stock Exchange of Hong Kong in June, 2019 (stock code: 03692.HK). For more information, please visit www.hspharm.com